GlassScriptPhysician profile
Sam S Yeh
NPI 1689741498
$10,384.74
in general payments reported to CMS, 2019-2025
32 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $57.49 · 2021: $1,946 · 2022: $1,203 · 2023: $1,494 · 2024: $3,718 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,700 · Food and Beverage: $881 · Honoraria: $360 · Travel and Lodging: $250 · Education: $91.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,700.00 |
| Food and Beverage | $881.49 |
| Honoraria | $360.00 |
| Travel and Lodging | $250.00 |
| Education | $91.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,755.85 | 2019-2024 | Imfinzi, Truqap |
| E.R. Squibb & Sons, L.L.C. | $1,337.14 | 2019-2024 | Opdivo |
| Daiichi Sankyo INC. | $1,010.00 | 2023-2025 | Vanflyta |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $600.00 | 2022-2024 | |
| Incyte Corporation | $500.00 | 2023 | |
| Genzyme Corporation | $375.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $350.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $350.00 | 2021 | |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Amgen INC. | $274.35 | 2019-2021 | |
| Abbvie INC. | $257.72 | 2022-2023 | Venclexta |
| Ipsen Biopharmaceuticals, INC | $251.53 | 2021 | |
| Emd Serono, INC. | $180.61 | 2023 | Bavencio |
| Karyopharm Therapeutics INC. | $150.55 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $149.15 | 2022 | |
| Servier Pharmaceuticals LLC | $124.99 | 2021 | |
| Eisai INC. | $119.18 | 2022 | |
| Immunocore Limited | $109.79 | 2024-2025 | Kimmtrak |
| Aveo Pharmaceuticals, INC. | $91.40 | 2025 | |
| Jazz Pharmaceuticals INC. | $71.29 | 2023 | |
| Gilead Sciences, INC. | $60.98 | 2019 | |
| Astellas Pharma US INC | $48.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.62 | 2019 | |
| Merck Sharp & Dohme LLC | $43.80 | 2019 | |
| Puma Biotechnology, INC. | $38.74 | 2019 | |
| Clinigen, INC. | $36.14 | 2019 | |
| Celgene Corporation | $27.39 | 2019 | |
| Lilly USA, LLC | $24.53 | 2020 | |
| Taiho Oncology, INC. | $19.54 | 2019 | |
| Kite Pharma, INC. | $18.93 | 2019 | |
| Pfizer INC. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.